What does Vifor make?
pharmaceutical products
Vifor Pharma Group develops, manufactures and markets pharmaceutical products including prescription and non-prescription products.
What is vifor used for?
Vifor is an 88-year-old specialty pharmaceutical company which markets iron deficiency, nephrology and cardio-renal products in more than 100 countries. Its pipeline is focused on developing new treatments for kidney disease.
Is Vifor Pharma a legit company?
Is Vifor Pharma a good company to work for? Vifor Pharma has an overall rating of 3.0 out of 5, based on over 104 reviews left anonymously by employees. 42% of employees would recommend working at Vifor Pharma to a friend and 39% have a positive outlook for the business.
Where is Vifor Pharma located?
St. Gallen, Switzerland 71,999 followers.
Who acquired vifor?
CSL
In a move to diversify its business, Australian biopharma CSL has agreed to acquire Vifor Pharma for $11.7 billion. The deal would give CSL—heavily dependent on vaccines and blood plasma products—Vifor’s attractive kidney disease and iron deficiency franchises.
Who bought Vifor Pharma?
CSL Limited
CSL Limited, parent company to CSL Behring, recently announced its intent to acquire Vifor Pharma, a global specialty pharmaceutical company with leadership positions in iron deficiency, nephrology (kidney care) and cardio-renal therapies.
Who acquired Vifor?
Did CSL acquire Vifor?
Stocks watchers are focusing on the value CSL can extract from its blockbuster acquisition of Swiss pharma firm Vifor as turbulence in the listed biotech giant’s plasma business starts to stabilise.
How many employees does Vifor Pharma have?
Latest Updates
| Employees (est.) (Jun 2022) | 2,200 | (-7%) |
|---|---|---|
| Job Openings | 84 | |
| Revenue (FY, 2021) | CHF1.8 B | (-3%) |
| Share Price (Jun 2022) | CHF171.4 | |
| Cybersecurity rating | B | More |
Did CSL buy vifor?
In a move to diversify its business, Australian biopharma CSL has agreed to acquire Vifor Pharma for $11.7 billion. The deal would give CSL—heavily dependent on vaccines and blood plasma products—Vifor’s attractive kidney disease and iron deficiency franchises.
Did CSL buy Vifor?
Who bought vifor?
CSL to buy Vifor for $11.7B in biopharma’s largest M&A deal this year. In a move to diversify its business, Australian biopharma CSL has agreed to acquire Vifor Pharma for $11.7 billion.
Did CSL acquire vifor?
Why choose Ettingen as your Pharma manufacturer?
CordenPharma Ettingen is an expert manufacturer of semi-solid dosage forms and non-sterile liquid drug products, offering a full range of services from pharmaceutical development for phase I-III and commercial scale manufacturing, to packaging and pharma-logistics for a global market.
Why choose Vifor Pharma?
We strive to help patients with severe and chronic disease lead better, healthier lives. Vifor Pharma is committed to improving the lives of patients around the world with the development of innovative pharmaceutical products.
Why CordenPharma Ettingen?
As a former Vifor Pharma operations site, CordenPharma Ettingen brings over 45 years of experience to CordenPharma’s full-service CDMO platform. The site is inspected by Swissmedic and the Russian Authorities.
Where can Vifor Pharma clinical research be reported?
Currently, Vifor Pharma clinical research is registered and reported using publicly accessible websites sponsored by the regulatory authorities in the US and Europe.